Drug Database · Clinicians

Norfloxacin

Brands (5) Prostacin, Flamorel, Flornox…Show all

Antibacterial (quinolone); Urinary antiseptic (quinolone) PH FDA category

CrCl <30: 400 mg once dailyRx · Prescription drug6 PH products Kidney dosing reviewed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals

Contraindications

  • Hypersensitivity to quinolones
  • History of fluoroquinolone tendinopathy
  • Pre-pubertal children
  • Pregnancy
renalcarematters.com, reviewed

Dosing: Adult

  • Urinary tract infection: 400 mg twice daily for 7 to 10 days
  • Chronic bacterial prostatitis: 400 mg twice daily for 3 to 7 weeks
  • Acute bacterial gastroenteritis: 400 mg twice daily for 5 days
  • Uncomplicated gonorrhea: 800 mg single dose
renalcarematters.com, reviewed

Dosing: Altered kidney function

Norfloxacin is a fluoroquinolone excreted largely unchanged in urine (33% to 48% in 24 hours); its half-life rises from 3–4 hours to about 8 hours at creatinine clearance (CrCl) below 30 mL/min/1.73 m2. The New Zealand data sheet halves the daily dose to 400 mg once daily at CrCl below 30 (not on hemodialysis) and has no data for gonorrhea in that group. Fluoroquinolone class warnings apply. It has no current US FDA label.

Kidney function measure: New Zealand data sheet uses creatinine clearance indexed to body surface area (CrCl, mL/min/1.73 m2); threshold 30.

Show full dosing details
CrCl ≥60 mL/min
Usual: 400 mg twice daily (urinary tract infection 7 to 10 days; gastroenteritis 5 days; chronic prostatitis 3 to 7 weeks); maximum 800 mg/day (data sheet).
CrCl 30–59 mL/min
No dose change at CrCl ≥30 (data sheet).
CrCl 15–29 mL/min
CrCl <30 (not on hemodialysis): 400 mg once daily. No dose recommendation for gonorrhea at CrCl ≤30 (data sheet).
CrCl <15 mL/min (not on dialysis)
400 mg once daily; half-life about 8 hours, the same at CrCl <10 and 10–30 (data sheet). Low urinary levels may limit efficacy in urinary infections (our caution).
Hemodialysis (intermittent)
The data sheet's reduced dose excludes patients on hemodialysis; no hemodialysis dosing is given. Specialist input; consider another agent.
Peritoneal dialysis
No PD dosing in the data sheet.
CRRT
No data; oral agent rarely used in CRRT settings.
  • Dialyzable? Not stated.
  • Monitoring Tendinopathy (higher risk with kidney impairment, transplant, corticosteroids, age); QT risk factors; glucose with sulfonylureas or insulin (dysglycemia, hypoglycemic coma); seizures; hydration (crystalluria). Separate from iron, zinc, antacids, sucralfate by 2 hours (data sheet). Fluoroquinolone restrictions: avoid for mild or self-limiting infections and, unless alternatives are unsuitable, uncomplicated cystitis; special caution over 60 years, in kidney impairment and after transplant (data sheet).
Children (kidney dosing)
eGFR ≥60
Contraindicated in pre-pubertal children; not for growing adolescents.
eGFR 30–59
Contraindicated in pre-pubertal children; not for growing adolescents.
eGFR 15–29
Contraindicated in pre-pubertal children; not for growing adolescents.
eGFR <15 (not on dialysis)
Contraindicated in pre-pubertal children; not for growing adolescents.
Hemodialysis (intermittent)
Contraindicated in pre-pubertal children; not for growing adolescents.
Peritoneal dialysis
Contraindicated in pre-pubertal children; not for growing adolescents.
CRRT
Contraindicated in pre-pubertal children; not for growing adolescents.

Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.

renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.

Source: Medsafe (New Zealand) product information (May 19, 2025). This generic has no US FDA label.

Dosing: Pediatric

Approved ages
Contraindicated in pre-pubertal children; not for growing adolescents (data sheet).
Usual dose
Not applicable.

Kidney dosing in children: see Dosing: Altered kidney function.

renalcarematters.com, reviewed

Dosage forms

Philippines

  • Film-coated tablet: 400 mg
  • Tablet: 200 mg, 400 mg

Registered products in the Philippines

6 products registered with the Food and Drug Administration (FDA) Philippines list Norfloxacin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products6
Philippine FDA-registered products for Norfloxacin
Package insert
FlamorelNorfloxacin
400 mg TabletAlu/PVC Blister Pack x 10's Box of 100's
Rx
Flamingo Pharmaceuticals Ltd.India
Hexagon Pharmaceuticals
DR-XY27822
Sep 9, 2027
FlornoxNorfloxacin
400 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's)
Rx
Centurion Remedies Pvt. Ltd.India
TGP Pharma Inc.Importer: Philgen Pharmaceuticals Inc.
DRP-1984
Jul 9, 2029
ProstacinNorfloxacin
200 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's)
Rx
Drugmaker's Laboratories, Inc.Philippines
—
DRP-5718
Oct 18, 2028
ProstacinNorfloxacin
400 mg TabletAlu/ Clear PVDC Blister Pack x 10's (Box of 100's)
Rx
Drugmaker’s Laboratories Inc.Philippines
—
DRP-5826
Oct 6, 2029
Urinox 400Norfloxacin
400 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's)
Rx
Centurion Remedies Pvt. Ltd.India
Meedpharma Medical Supplies & Equipment DistributorImporter: Philgen Pharmaceuticals Inc.
DRP-1984-01
Jul 9, 2029
UritracinNorfloxacin
400 mg Film-coated TabletAluminum Strip Foil x 10's Box of 100's
Rx
Amherst Laboratories, Inc.Philippines
Trader: RITEMED PHILS., INC.
DR-XY36232
Jul 13, 2029

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Drug interactions

Drug or classSeverityEffectWhat to do
Iron, zinc, multivitamins, magnesium or aluminum antacids, sucralfate, didanosineAdjust or monitorLower absorption.Do not take within 2 hours of norfloxacin.
Theophylline, CYP1A2 substrates (clozapine, tizanidine), caffeineAdjust or monitorHigher levels.Monitor levels; adjust.
WarfarinAdjust or monitorINR rise.Monitor prothrombin time.
CyclosporineAdjust or monitorHigher cyclosporine levels.Monitor levels.
Sulfonylureas, insulinAdjust or monitorDysglycemia, hypoglycemic coma.Monitor glucose.
CorticosteroidsAdjust or monitorTendon rupture.Avoid combination where possible.
NSAIDsAdjust or monitorSeizure risk.Use with caution.
Dairy, enteral nutritionMinorLower absorption.Take 1 hour before or 2 hours after.

Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.

renalcarematters.com, reviewed

Adverse reactions

Serious

  • Tendinitis and tendon rupture
  • QT prolongation, torsades de pointes
  • Seizures, peripheral neuropathy, psychiatric reactions
  • Aortic aneurysm and dissection
  • Hypoglycemic coma
  • Myasthenia gravis exacerbation
  • Clostridioides difficile colitis; DRESS; anaphylaxis
renalcarematters.com, reviewed

Monitoring parameters

  • Tendinopathy (higher risk with kidney impairment, transplant, corticosteroids, age); QT risk factors; glucose with sulfonylureas or insulin (dysglycemia, hypoglycemic coma); seizures; hydration (crystalluria). Separate from iron, zinc, antacids, sucralfate by 2 hours (data sheet). Fluoroquinolone restrictions: avoid for mild or self-limiting infections and, unless alternatives are unsuitable, uncomplicated cystitis; special caution over 60 years, in kidney impairment and after transplant (data sheet). Kidney
  • Fluoroquinolone restrictions: not for mild or self-limiting infections; caution over 60 years, in kidney impairment and after transplant
  • Tendon symptoms
  • Glucose in diabetes
  • ECG if QT risk factors
renalcarematters.com, reviewed

Pharmacokinetics

Key PK parameters

BioavailabilityAt least 30% to 40% absorbed
Time to peakAbout 1 hour
Half-life3 to 4 hours
Half-life in kidney failure (ESKD) kidneyAbout 8 hours at CrCl <30 (no difference between <10 and 10–30)
Protein binding10% to 15%
Renal excretion kidney33% to 48% unchanged in urine in 24 hours; about 30% in feces; renal clearance about 275 mL/min
Dialyzability kidneyNot stated
renalcarematters.com, reviewed

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. Medsafe (New Zealand Medicines and Medical Devices Safety Authority). Arrow-Norfloxacin 400 mg tablets data sheet [Medsafe (New Zealand) product information, May 19, 2025; no US FDA label]. https://www.medsafe.govt.nz/profs/datasheet/a/ArrowNorfloxacintab.pdf
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. Teva Pharma (New Zealand) Limited. (2025). Arrow-Norfloxacin 400 mg film-coated tablets [New Zealand data sheet, version 2.0; revised May 19, 2025]. Medsafe, New Zealand Medicines and Medical Devices Safety Authority. https://www.medsafe.govt.nz/profs/datasheet/a/ArrowNorfloxacintab.pdf

renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .